Skip to main content

EMC10 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 55 bp deletion in exon 1 and 73 bp deletion in exon 1.

Be the first to review this product! Submit a review

Images

Western blot - Human EMC10 (C19orf63) knockout HeLa cell line (AB265783), expandable thumbnail
  • Western blot - Human EMC10 (C19orf63) knockout HeLa cell line (AB265783), expandable thumbnail
  • Sanger Sequencing - Human EMC10 (C19orf63) knockout HeLa cell line (AB265783), expandable thumbnail
  • Sanger Sequencing - Human EMC10 (C19orf63) knockout HeLa cell line (AB265783), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, 55 bp deletion in exon 1 and 73 bp deletion in exon 1

Alternative names

Chromosome 19 open reading frame 63, EMC10_HUMAN, ER membrane protein complex subunit 10, HSM1, HSS1, Hematopoietic signal peptide containing membrane domain containing 1, Hematopoietic signal peptide containing secreted 1, Hematopoietic signal peptide-containing membrane domain-containing protein 1, INM02, UPF0510 protein INM02

Recommended products

EMC10 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 55 bp deletion in exon 1 and 73 bp deletion in exon 1.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, 55 bp deletion in exon 1 and 73 bp deletion in exon 1
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
EMC10
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

The C19orf63 protein also known as MRG domain-binding protein (MRGBP) works mechanically as a component of the histone acetyltransferase complex. It weighs approximately 19 kDa and is expressed in various human tissues with notable expression in HeLa cells. This protein is integral to chromatin modifications influencing transcription regulation through histone acetylation.

Biological function summary

C19orf63 interacts within the histone acetyltransferase complex playing a role in the modification of chromatin structure. It participates in transcriptional regulation by modulating the acetylation state of histones thereby impacting gene expression. This protein does not work alone and requires interaction with other proteins to execute its function efficiently.

Pathways

C19orf63 operates in pathways related to chromatin modification and transcription control. The protein influences the regulation of transcriptional signaling pathways such as the acetylation-dependent signaling pathway. C19orf63 associates with proteins like PCAF a known histone acetyltransferase working together to maintain gene accessibility and transcription fidelity.

Associated diseases and disorders

C19orf63 has connections with certain cancers through its role in chromatin structure and function alteration. Abnormal expression of this protein might contribute to tumorigenesis by altering gene expression profiles. Through the histone modification pathway it connects with proteins like BRCA1 which is involved in DNA repair and is associated with breast cancer.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

4 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com